A multicentre, retrospective study of rufinamide as an add-on therapy in patients with developmental and epileptic encephalopathies (DEE) and related electroclinical patterns (REP)
Latest Information Update: 17 Feb 2021
At a glance
- Drugs Rufinamide (Primary) ; Valproic acid
- Indications Absence epilepsy; Dravet syndrome; Epilepsy; Generalised epilepsy; Infantile spasms; Myoclonic epilepsies; Seizures; Tonic-clonic epilepsy
- Focus Adverse reactions; Therapeutic Use
- 17 Feb 2021 New trial record